Open access

265 Phase 1b study of avelumab + M9241 (NHS-IL12) in patients with advanced solid tumors: interim analysis results from a urothelial carcinoma (UC) dose-expansion cohort
Jean-Laurent Deville, Alain Ravaud, Marco Maruzzo, Theodore Gourdin, Michele Maio, Luc Dirix, XiaoZhe Wang, Yulia Vugmeyster, Frank Beier, Jeorg Seebeck, Sarah Chennoufi, James Gulley

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A163; DOI: 10.1136/jitc-2020-SITC2020.0265
274 Tumoral and peripheral immunophenotype of refractory vs relapse to PD-(L)1 blockade in patients with advanced non-small cell lung cancer
Maria Ascierto, Matthew Hellmann, Nathan Standifer, Song Wu, Han Si, Chris Morehouse, Marlon Rebelatto, Shaad Abdullah, Rajiv Raja, Jean-Charles Soria, Caroline Germa, Carl Barrett

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A167; DOI: 10.1136/jitc-2020-SITC2020.0274
276 Prognostic value of tumor size varies by treatment in a meta-analysis of 15 randomized clinical trials in advanced non-small cell lung cancer across immunotherapy, TKI, and chemotherapy regimens
Jacqueline Buros, Krzysztof Sakrejda, Daniel Lee, Eric Novik, Philip Jewsbury

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A168-A169; DOI: 10.1136/jitc-2020-SITC2020.0276
280 Both tumor intrinsic and extrinsic factors contribute to TIL resistance in lung cancer patients
Chao Wang, Jamie Teer, Jiqiang Yao, Carmen Anadon, David Noyes, Ana Landin, Xiaoqing Yu, Dongliang Du, Zachary Thompson, Bin Fang, John Koomen, Sungjune Kim, Shari Pilon-Thomas, Dung-Tsa Chen, Jose Conejo-Garcia, Scott Antonia, Eric Haura, Ben Creelan

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A170-A171; DOI: 10.1136/jitc-2020-SITC2020.0280
279 Durvalumab after chemoradiotherapy for PD-L1 expressing inoperable stage III NSCLC impacts local-regional control and overall survival
Lukas Kaesmann, Julian Taugner, Chukwuka Eze, Claus Belka, Farkhad Manapov

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A170; DOI: 10.1136/jitc-2020-SITC2020.0279
281 JAVELIN Medley VEGF: phase 2 study of avelumab + axitinib in patients with previously treated non-small cell lung cancer (NSCLC) or treatment naive, cisplatin-ineligible urothelial cancer (UC)
Gabriella Galffy, Iwona Lugowska, Elena Poddubskaya, Byoung Chul Cho, Myung-Ju Ahn, Ji-Youn Han, Wu-Chou Su, Ralph Hauke, Stephen Dyar, Dae Ho Lee, Piotr Serwatowski, David Lorente Estelles, Viran Holden, Yu Jung Kim, Vladimir Vladimirov, Zsolt Horvath, Abhimanyu Ghose, Allison Goldman, Alessandra di Pietro, Jing Wang, Danielle Murphy, Mikhail Laskov

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A171-A172; DOI: 10.1136/jitc-2020-SITC2020.0281
283 Safety and efficacy signals in the complete phase I study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors (ICIs)
Shubham Pant, Amishi Shah, Pavlos Msaouel, Matthew Campbell, Shi-Ming Tu, Jianjun Gao, George Blumenschein, Frank Mott, Xiuning Le, Mehmet Altan, Funda Meric-Bernstam, Timothy Yap, Vivek Subbiah, Jordi Rodon, Axel Glasmacher, Imke Mulder, Michael Chisamore, Alexander Stevenson, Nizar Tannir

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A173; DOI: 10.1136/jitc-2020-SITC2020.0283
288 A phase 1 study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors
Bhumsuk Keam, Tae Min Kim, Do-Youn Oh, Chan-Young Ock, Won Ki Kang, Yeon Hee Park, Jeeyun Lee, Ji Hye Lee, Yun Jeong Song, Young Suk Park

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A176; DOI: 10.1136/jitc-2020-SITC2020.0288
290 Cytokine and immune subset signatures in patients with various solid and hematological malignancies treated with oncolytic vaccinia virus delivered by autologous stromal vascular fraction cells
Dobrin Draganov, Antonio Santidrian, Ivelina Minev, Duong Nguyen, Dmitriy Zamarin, Francesco Marincola, Boris Minev

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A177; DOI: 10.1136/jitc-2020-SITC2020.0290
292 Immune checkpoint inhibitor induced overlapping cardiac and neuromuscular toxicities: Highlight of early diagnosis, early initiation of immunosuppressive therapy and multidisciplinary management
Ho Wai Siu, Robert O’Neill, Matthew Tong, JunHee Hong, Carole A Harris, Morteza Aghmesheh, Hussein Soudy

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A178-A179; DOI: 10.1136/jitc-2020-SITC2020.0292

Main menu

Open access

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Open access

Pages